ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1340

Does Moderate Alcohol Use Lower Disease Activity Among Patients with Rheumatoid Arthritis?

Sarah Crisci1, Joshua Baker2, Kevin Kane3, George Reed4, Dimitrios Pappas5 and Joel Kremer6, 1New York University, New York, NY, 2University of Pennsylvania, Philadelphia, PA, 3University of Massachusetts Lowell, Lowell, MA, 4University of Massachusetts Chan Medical School, Worcester, MA, 5CorEvitas, New York, NY, 6The Corrona Research Foundation, Delray Beach, FL

Meeting: ACR Convergence 2025

Keywords: rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The relationship between alcohol use and disease activity among patients with rheumatoid arthritis (RA) remains controversial. Several studies have concluded that moderate drinking may be beneficial for individuals with RA. However, recent concerns about residual confounding have arisen within studies aimed at understanding causal risks of alcohol. This is because non-drinkers may have stopped consuming alcohol because of adverse health. Recent efforts in epidemiologic studies to define occasional use of alcohol as the reference may help reduce this bias. This study aimed to explore associations between alcohol use and clinical disease activity index (CDAI) among RA patients in a large sample, comparing the estimates of association when using non-drinkers or, alternatively, occasional drinkers as the comparison group.

Methods: This cross-sectional study assessed the association between disease activity and frequency of alcohol use, using data from the CorEvitas Rheumatoid Arthritis Registry, a prospective, observational, multi-site study of adults with RA. All patients in the Registry were provided-diagnosed. One visit per patient was randomly chosen, excluding the enrollment visit or last visit. Drinking is patient reported and divided into 6 categories. The association of mean CDAI with drinking categories was estimated using linear regression. A series of nested models adjusted for demographics and drug use, +comorbidities, and +pain and psychosocial factors. Estimates used “Not at All” or “Occasionally” as the reference category in the models.

Results: A total of 30,995 adults with non-missing confounding variables were included in this study. Non-drinkers had higher rates of disability, comorbidities (including diabetes, CAD, CHF, hypertension, obesity, and fibromyalgia), opioid use, depression, and anxiety; as well as higher scores for physician and patient global assessments, tender and swollen joints, pain, and fatigue compared to other categories (Table 1). Compared to non-drinkers, any amount of drinking was associated with a lower CDAI with the greatest apparent benefit observed for moderate drinkers. [Unadjusted β: -3.65 (95 % CI: -4.16, -3.14)]. This was somewhat attenuated with adjustment for confounders [Fully adjusted β: -2.42 (95% CI: -2.91, -1.93)] (Table 2). The unadjusted estimate for moderate drinkers was reduced substantially when using occasional drinkers as the reference group. [Unadjusted β: -1.85 (95% CI -2.43, -1.17)] and was further attenuated with adjustment [β: -1.11 (95% CI: -1.66, -0.56)]. Figure 1 shows the mean difference in CDAI for the fully adjusted models.

Conclusion: Light to moderate alcohol use was associated with lower disease activity in patients with RA, with moderate users seeing the biggest reduction in CDAI. However, the amount of observed benefit was far less when comparing moderate use to occasional use and after adjustment for confounding factors. These data raise questions regarding the accuracy of the estimated benefit of alcohol from prior studies where non-drinkers were used as the reference group and suggests that residual confounding is likely. A biologic mechanism for a benefit of alcohol effect is not known.

Supporting image 1Table 1: Baseline characteristics by alcohol use frequency

Supporting image 2Table 2: Estimated CDAI by drinking category using tiered models

Supporting image 3Difference in Mean CDAI in fully adjusted models using “Not At All” or “Occasionally” as the reference group


Disclosures: S. Crisci: CorEvitas, part of Thermo Fisher Scientific, 3; J. Baker: Amgen, 5; K. Kane: None; G. Reed: CorEvitas, part of Thermo Fisher Scientific, 2, Corrona Research Foundation, 2; D. Pappas: AbbVie/Abbott, 2, CorEvitas, Part of Thermofisher, 3, 11, Corrona Research Foundation, a not-for-profit 501(c)3 foundation, 4, Novartis, 2, Roche, 2; J. Kremer: CorEvitas (part of ThermoFisher), 1, Corrona Research Foundation, a not-for-profit 501(c)3 foundation, 4.

To cite this abstract in AMA style:

Crisci S, Baker J, Kane K, Reed G, Pappas D, Kremer J. Does Moderate Alcohol Use Lower Disease Activity Among Patients with Rheumatoid Arthritis? [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/does-moderate-alcohol-use-lower-disease-activity-among-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-moderate-alcohol-use-lower-disease-activity-among-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology